NCT00712868

Brief Summary

To demonstrate the safety and acceptability of the gynaecological formulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
559

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jun 2008

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 7, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 10, 2008

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2008

Completed
Last Updated

July 20, 2009

Status Verified

July 1, 2009

Enrollment Period

2 months

First QC Date

July 7, 2008

Last Update Submit

July 17, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical and local tolerability

    After 21 days

Study Arms (1)

1

EXPERIMENTAL

Lactic Acid once a day during 21 days

Drug: Lactic acid

Interventions

Once a day

1

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Integral skin in the tested region

You may not qualify if:

  • Pregnancy or breastfeeding women
  • Use of anti-inflammatory or immune-suppression drugs
  • Topical medication use at the tested region
  • Active cutaneous gynaecological disease which may interfere in study results
  • Personal history of allergic disease at the area to be treated
  • Allergic or atopic history
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sanofi-Aventis Administrative Office

Col. Coyoacan, Mexico

Location

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

  • Judith Diaz, Md

    Sanofi

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

July 7, 2008

First Posted

July 10, 2008

Study Start

June 1, 2008

Primary Completion

August 1, 2008

Study Completion

August 1, 2008

Last Updated

July 20, 2009

Record last verified: 2009-07

Locations